HABA LABORATORIES,INC. [4925.T]
TOKYO, May 28 (Pulse News Wire) – Haba Laboratories,inc. (4925.T) revised its numerical targets for fiscal year 2028 (ending March 2028) within its second mid-term management plan covering fiscal years 2026 through 2028.
The adjustments were approved during the board meeting held. According to the revised plan, the projected revenue for fiscal year 2028 is now set at ¥13.70 billion compared to the initial target of ¥16.00 billion. Similarly, operating profit is adjusted down to ¥950 million from the previous estimate of ¥1.200 billion.
The operating margin is also revised from 7.5% to 6.9%. The revisions come amid concerns over slower-than-expected sales realization timelines, customer acquisition challenges, and evolving global economic conditions. As a result, the company is shifting its focus towards a more stable growth model prioritizing profitability and efficiency rather than rapid expansion.
HABA Laboratories emphasized that while these projections are based on available data and certain assumptions as of the release date, future performance could differ significantly due to various unforeseen factors.
🟢 Confidence: High AI-translated content.